Cost-effectiveness and drug wastage of bevacizumab biosimilar with or without chemotherapy for platinum-resistant recurrent ovarian cancer

References

• American cancer society. Available from: https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html
   Google Scholar
• Health Promotion Administration, Ministry Of Health And Welfare. Available from: https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html
   Google Scholar
• Saani I, Raj N, Sood R, et al. Clinical challenges in the management of malignant ovarian germ cell tumours. Int J Environ Res Public Health. 2023;20(12):6089. doi: 10.3390/ijerph20126089
   PubMedGoogle Scholar
• Moschetta M, Boussios S, Rassy E, et al. Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going? Ann Transl Med. 2020;8(24):1710. doi: 10.21037/atm-20-1683
   PubMed Web of Science ®Google Scholar
• NCCN Guidelines Version 2. 2023 Ovarian cancer. National comprehensive cancer network. [cited 2023 Jan7]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf
   Google Scholar
• Harter P, Mouret-Reynier MA, Pignata S, et al. Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. Gynecol Oncol. 2022;164(2):254–264. doi: 10.1016/j.ygyno.2021.12.016
   PubMed Web of Science ®Google Scholar
• Ghose A, Gullapalli SVN, Chohan N, et al. Applications of proteomics in ovarian cancer: dawn of a new era. Proteomes. 2022;10(2):16. doi: 10.3390/proteomes10020016
   PubMed Web of Science ®Google Scholar
• Takaya H, Nakai H, Takamatsu S, et al. Homologous recombination deficiency status-based classification of high-grade serous ovarian carci noma. Sci Rep. 2020;10(1):2757.
   PubMed Web of Science ®Google Scholar
• Bogani G, Lopez S, Mantiero M, et al. Immunotherapy for platinum-resistant ovarian cancer. Gynecol Oncol. 2020;158(2):484–488. doi: 10.1016/j.ygyno.2020.05.681
   PubMed Web of Science ®Google Scholar
• Shah S, Cheung A, Kutka M, et al. Epithelial ovarian cancer: providing evidence of predisposition genes. Int J Environ Res Public Health. 2022;19(13):8113. doi: 10.3390/ijerph19138113
   PubMed Web of Science ®Google Scholar
• Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25(33):5180–5186. doi: 10.1200/JCO.2007.12.0782
   PubMed Web of Science ®Google Scholar
• McGonigle KF, Muntz HG, Vuky J, et al. Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study. Cancer. 2011;117(16):3731–3740. doi: 10.1002/cncr.25967
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302–8. doi: 10.1200/JCO.2013.51.4489
   PubMed Web of Science ®Google Scholar
• Tichy EM, Hoffman JM, Suda KJ, et al. Tadrous M, et al.National trends in prescription drug expenditures and projections for 2022. Am J Health Syst Pharm. 2022;79(14):1158–1172. doi: 10.1093/ajhp/zxac102
   PubMed Web of Science ®Google Scholar
• Ghose A, Bolina A, Mahajan I, et al. Hereditary ovarian cancer: towards a cost-effective prevention strategy. Int J Environ Res Public Health. 2022;19(19):12057. doi: 10.3390/ijerph191912057
   PubMed Web of Science ®Google Scholar
• Taiwan Pharmaceutical Manufacture and development. http://www.cpmda.org.twnews_show_n1
   Google Scholar
• Goldstein DA, Chen Q, Ayer T, et al. Bevacizumab for metastatic colorectal cancer: a global Cost-Effectiveness Analysis. Oncology. 2017;22(6):694–699. doi: 10.1634/theoncologist.2016-0455
   Google Scholar
• Kovic B, Xie F. Economic evaluation of bevacizumab for the first-line treatment of newly diagnosed glioblastoma multiforme. J Clin Oncol. 2015;33(20):2296–2302. doi: 10.1200/JCO.2014.59.7245
   PubMed Web of Science ®Google Scholar
• Shao C, Siddiqui MK, Takyar J, et al. Economic burden of advanced cervical cancer: a systematic literature review. Value Health. 2018;21:S27. doi: 10.1016/j.jval.2018.04.170
   PubMedGoogle Scholar
• Ball G, Xie F, Tarride JE. Economic evaluation of bevacizumab for treatment of platinum-resistant recurrent ovarian cancer in Canada. Pharmacoecon Open. 2018;2(1):19–29. doi: 10.1007/s41669-017-0030-7
   PubMedGoogle Scholar
• WZ W, EM S, Coles T, et al. Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: a cost effectiveness analysis of the AURELIA trial. Gynecol Oncol. 2017;145(2):340–345.
   PubMed Web of Science ®Google Scholar
• Shoji T, Enomoto T, Abe M, et al. Efficacy and safety of standard of care with/without bevacizumab for platinum-resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: the Japanese Gynecologic Oncology Group study JGOG3023. Cancer Sci. 2022;113(1):240–250. https://www.lotuspharm.com/newsroom/lotus-received-approval-for-alymsys-in-taiwan
   PubMed Web of Science ®Google Scholar
• Guangying D, Shuzhi M, Xiaoyin Z, et al. Non-clinical pharmacology and toxicology studies of bevacizumab biosimilar LY01008. Eur J Pharmacol. 2022;936:175383. doi: 10.1016/j.ejphar.2022.175383
   PubMed Web of Science ®Google Scholar
• Jia H, Harikumar P, Atkinson E, et al. The First WHO International Standard for harmonizing the biological activity of Bevacizumab. Biomolecules. 2021;11(11):1610. doi: 10.3390/biom11111610
   PubMed Web of Science ®Google Scholar
• Diaby V, Ali AA, Adunlin G, et al. Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients. Curr Med Res Opin. 2016;32(6):991–996.26. doi: 10.1185/03007995.2016.1149056
   PubMed Web of Science ®Google Scholar
• Leung JH, Tai YS, Wang SY, et al. Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer. Breast. 2022;65:91–97. doi: 10.1016/j.breast.2022.07.007
   PubMed Web of Science ®Google Scholar
• Ministry Of Health And Welfare, Department of statistics, Taiwan. [cited 2023 Mar 23]. Available from:https://www.mohw.gov.tw/lp-4614-2.html
   Google Scholar
• Diaby V, Adunlin G, Ali AA, et al. Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. Breast Cancer Res Treat. 2016;160(1):187e96. doi: 10.1007/s10549-016-3978-6
   Web of Science ®Google Scholar
• Havrilesky LJ, Broadwater G, Davis DM, et al. Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment. Gynecol Oncol. 2009;113(2):216–20. doi: 10.1016/j.ygyno.2008.12.026
   PubMed Web of Science ®Google Scholar
• Wysham WZ, Schaffer EM, Coles T, et al. Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: a cost effectiveness analysis of the AURELIA trial. Gynecol Oncol. 2017;145(2):340–345. doi: 10.1016/j.ygyno.2017.02.039
   PubMed Web of Science ®Google Scholar
• Briggs AH, Weinstein MC, Fenwick EAL, et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group-6. Med Decis Mak Int J Soc Med Decis Mak. 2012;32(5):722–732. doi: 10.1177/0272989X12458348
   PubMed Web of Science ®Google Scholar
• World Health Organization. World Health Organization, cost-effectiveness thresholds. 2023. [cited 2023 Dec 30]. Available from: 〈http://www.who.int/choice/costs/CER_thresholds/en/index.html〉
   Google Scholar
• Yang J, Liu R, Ektare V, et al. Does biosimilar bevacizumab offer affordable treatment options for cancer patients in the USA? A Budget Impact Analysis from US commercial and medicare payer perspectives. Appl Health Econ Health Policy. 2021 Jul;19(4):605–618.
   PubMed Web of Science ®Google Scholar
• Peipert JD, Kaiser K, Kircher S, et al. Medical oncologists’ knowledge and perspectives on the Use of Biosimilars in the United States. JCO Oncol Pract. 2023 Mar;19(3):e457–e464.
   PubMedGoogle Scholar
• Giuliani J, Bonetti A. The economic impact of biosimilars in oncology and hematology: the case of trastuzumab and rituximab. Anticancer Res. 2019;39(7):3971–3973. doi: 10.21873/anticanres.13552
   PubMed Web of Science ®Google Scholar
• Giuliani J, Fiorica F, Albanese V, et al. Financial toxicity and cancer treatments: help from biosimilars - the explanatory case of bevacizumab. Eur J Cancer. 2021;143:40–42. doi: 10.1016/j.ejca.2020.11.004
   PubMed Web of Science ®Google Scholar
• MacDonald K, Alrawashdh N, McBride A, et al. Cost-efficiency analysis of conversion from reference pegfilgrastim to its biosimilar (pegfilgrastim-jmdb) and expanded access to food and transportation support for Medicare/Medicaid patients within the CMS oncology care Model. J Clin Oncol. 2021;39(Suppl 15):e18837. doi: 10.1200/JCO.2021.39.15_suppl.e18837
   Web of Science ®Google Scholar
• Valgus JM. Cancer drug wastage: the hidden cost in value-based cancer care delivery. Cancer. 2017;123(18):3445–3446. doi: 10.1002/cncr.30805
   PubMed Web of Science ®Google Scholar
• Kurki P, van Aerts L, Wolff-Holz E, et al. Interchangeability of biosimilars: a Europeanperspective. BioDrugs. 2017;31(2):83–91. doi: 10.1007/s40259-017-0210-0
   PubMed Web of Science ®Google Scholar
• Li E, Hoffman JM. Implications of the FDA draft guidance on biosimilars for clinicians: what we know and don’t know. J Natl Compr Canc Netw. 2013;2013(4):368–372. doi: 10.6004/jnccn.2013.0052
   Google Scholar
• Reinmuth N-O, Bryl M, Bondarenko I, et al. PF-06439535 (a bevacizumab biosimilar) compared with reference bevacizumab (Avastin®), both plus paclitaxel and carboplatin, as first-line treatment for advanced non-squamous non-small-cell lung cancer: a randomized, double-blind study. BioDrugs. 2019;2019(5):555–570. doi: 10.1007/s40259-019-00363-4
   Google Scholar